Daniel C. Danila

15.0k citations

130 papers · 6.6k indexed · 3 hit papers · h-index 34

Impact in

Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
- Cancer, Lipids, and Metabolism
Pulmonary and Respiratory Medicine top 0.5%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment

Papers in

Pulmonary and Respiratory Medicine 104
- Prostate Cancer Treatment and Research 101
Cancer Research 47
- Cancer Genomics and Diagnostics 29
- Cancer, Lipids, and Metabolism 10

Co-authors: Howard I. Scher Martin Fleisher Glenn Heller Aseem Anand Steven M. Larson Michael J. Morris Hans Lilja Dana E. Rathkopf
Journals: Journal of Clinical Oncology (63 papers)Annals of Oncology (9 papers)The Journal of Clinical Endocrinology & Metabolism (8 papers)Clinical Cancer Research (7 papers)European Urology (4 papers)
Partner nations: United States United Kingdom Spain

In The Last Decade

Daniel C. Danila

122 papers receiving 6.5k citations

Hit Papers

align trajectories log scale

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer 2016 · 461 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 JAMA Oncology
2010 The Lancet
2007 Clinical Cancer Research

Peers

Countries citing papers authored by Daniel C. Danila

Since Specialization

Citations

This map shows the geographic impact of Daniel C. Danila's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel C. Danila with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel C. Danila more than expected).

Fields of papers citing papers by Daniel C. Danila

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel C. Danila. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel C. Danila. The network helps show where Daniel C. Danila may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Daniel C. Danila, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel C. Danila Line = papers co-authored together Daniel C. Danila links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A phase 1b, open-label, multicenter study of xaluritamig in patients with biochemical recurrence of prostate cancer after definitive therapy. Journal of Clinical Oncology ·Ben Tran, Kevin D. Courtney, Alexandra Sokolova, Lisa G. Horvath, Daniel C. Danila, Jessica E. Hawley, David Pook, Landon C. Brown, Young E. Whang, Dong-Im Lee, Kejia Wang, Nicholas A. Zorko	2025	0
2	The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide Clinical Cancer Research ·Susan Halabi, E. v. Angerer, Joseph J. Park, David M. Nanus, Daniel J. George, Emmanuel S. Antonarakis, Daniel C. Danila, Russell Z. Szmulewitz, Donald P. McDonnell, John D. Norris, Changxue Lu, Jun Luo, Andrew J. Armstrong	2024	8
3	1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study Annals of Oncology ·William Kevin Kelly, Leonard J. Appleman, C-C. Lin, André Lavallée, Sabine Fischer, David Pook, (unknown), Jia-Lin Lee, Vincent N egrave gre, Phil Ward, Tomasz Kossak, Lisa G. Horvath, Isabella O. Conway, 장재희, Christopher Sumey, Y. Huet, Zhi Yang, Jamie N. Connarn, Julia Stieglmaier, Daniel C. Danila	2024	1
4	1610P Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig Annals of Oncology ·André Lavallée, 朝章安藤, Daniel C. Danila, C-C. Lin, Jia-Lin Lee, Robert Arie Frederick, Phil Ward, David Pook, Isabella O. Conway, Tanya B. Dorff, Sabine Fischer, Natasha Oquendo, Lisa G. Horvath, Christopher Sumey, Zhi Yang, Benjamin E. Decato, Alice Gerzson Araújo, Katherine Smith, Martijn P. Lolkema, William K. Kelly	2024	1
5	264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) Annals of Oncology ·William Kevin Kelly, Daniel C. Danila, C-C. Lin, Jia-Lin Lee, Nobuaki Matsubara, Phil Ward, Andrew J. Armstrong, David Pook, Isabella O. Conway, Tanya B. Dorff, Stefanie Fischer, 李允渙, Lisa G. Horvath, Christopher Sumey, Zhi Yang, Qishan Zhang, Jamie N. Connarn, Hugo A. Penny, Julia Stieglmaier, Leonard J. Appleman	2023	1
6	Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer SHILAP Revista de lepidopterología ·María Palma-Acosta, Mahsa Sadat Sarmalek, Daniel C. Danila, Michael J. Morris, Susan F. Slovin, Wassim Abida, C Billet, Raymond E. Baser, Howard I. Scher, Karen A. Autio	2023	2
7	PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer Clinical Cancer Research ·Cheng Jiang, Susan Halabi, Qian Yang, F. K. Ko, Papri Dutta, 弘泰伊東, Daniel J. George, David M. Nanus, Emmanuel S. Antonarakis, Daniel C. Danila, Russell Z. Szmulewitz, Richard Wenstrup, Andrew J. Armstrong	2023	15
8	582P Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD) Annals of Oncology ·Matthew R. Smith, Shahneen Sandhu, Daniel J. George, K.N. Chi, Fred Saad, Antoine Thiery-Vuillemin, O. Ståhl, David Olmos, Daniel C. Danila, Rustem Gafanov, Elena Castro, Helen Moon, Anthony M. Joshua, Gary Mason, Byron M. Espina, Marinela Štrbac, Katherine B. Bevans, Angela Lopez‐Gitlitz, Peter Francis, Karim Fizazi	2021	1
9	Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2 -altered Prostate Tumors Clinical Cancer Research ·Goutam Chakraborty, А. В. Ларионов, Rahim Hirani, Subhiksha Nandakumar, Ying Z. Mazzu, Yuki Yoshikawa, Mohammad Atiq, Gabriella Traverso, Konrad H. Stopsack, Gwo‐Shu Mary Lee, Wassim Abida, Michael J. Morris, Lorelei A. Mucci, Daniel C. Danila, Philip W. Kantoff	2020	17
10	Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer European Urology ·David Lorente, David Olmos, Joaquı́n Mateo, Diletta Bianchini, George Seed, Martin Fleisher, Daniel C. Danila, Penny Flohr, Mateus Crespo, Ines Figueiredo, Susana Miranda, Kurt Baeten, Arturo Molina, Thian Kheoh, Robert McCormack, Leon W.M.M. Terstappen, Howard I. Scher, Johann S. de Bono	2016	113
11	A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC) Annals of Oncology ·M. L. Cascajo Cardoso, Daniel C. Danila, Bruce Montgomery, Russell Z. Szmulewitz, Ulka N. Vaishampayan, Andrew J. Armstrong, Mark N. Stein, Christopher Hoimes, J. Pinski, Howard I. Scher, Loredana Puca, Rohan Bareja, Wai Wong, Mark A. Rubin, Juan Miguel Mosquera, Andrea Sboner, Clara Oromendia, David M. Nanus, Karla V. Ballman, Zbyšek Podhrázský	2016	11
12	A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naïve patients with progressive metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology ·Daniel C. Danila, Timothy M. Kuzel, Jeremy Cetnar, Dana E. Rathkopf, Michael J. Morris, Joshi J. Alumkal, Sul-U Park, Tracy Curley, Melanie Hullings, Wellinton M. do Nascimento, Julie Filipenko, Howard I. Scher	2016	2
13	Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer Journal of Clinical Oncology ·Howard I. Scher, Glenn Heller, Arturo Molina, Gerhardt Attard, Daniel C. Danila, Xiaoyu Jia, Weimin Peng, Shahneen Sandhu, David Olmos, Ruth Riisnaes, Robert G. McCormack, Tomasz Burzykowski, Thian Kheoh, Martin Fleisher, Marc Buyse, Johann S. de Bono	2015	294
14	Monitoring the Clinical Outcomes in Advanced Prostate Cancer: What Imaging Modalities and Other Markers Are Reliable? Seminars in Oncology ·Michael J. Morris, Karen A. Autio, Ethan Basch, Daniel C. Danila, Steven M. Larson, Howard I. Scher	2013	28
15	Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors Cancer Research ·Nicholas Mitsiades, Clifford C. Sung, Nikolaus Schultz, Daniel C. Danila, Bin He, Vijay Kumar Eedunuri, Martin Fleisher, Chris Sander, Charles L. Sawyers, Howard I. Scher	2012	175
16	Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer Journal of Clinical Oncology ·Daniel C. Danila, Michael J. Morris, Johann S. de Bono, Charles J. Ryan, Samuel R. Denmeade, Matthew R. Smith, Mary-Ellen Taplin, Glenn J. Bubley, Thian Kheoh, Christopher M. Haqq, Arturo Molina, Aseem Anand, S Liberson, Steven M. Larson, Lawrence H. Schwartz, Martin Fleisher, Howard I. Scher	2010	318
17	Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study The Lancet ·Howard I. Scher, Tomasz M. Beer, Celestia S. Higano, Aseem Anand, Mary‐Ellen Taplin, Eleni Efstathiou, Dana E. Rathkopf, Julia Shelkey, Evan Y. Yu, Joshi J. Alumkal, David T. Hung, Mohammad Hirmand, Lynn Seely, Michael J. Morris, Daniel C. Danila, John L. Humm, Steven M. Larson, Martin Fleisher, Charles L. Sawyers Hit paper breakdown →	2010	809
18	Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Oxford University Research Archive (ORA) (University of Oxford) ·(unknown), Jane Han, Zahra Asgari, Daniel C. Danila, Oscar Lin, Rita Gonzalez-Espinoza, Aseem Anand, Hans Lilja, Glenn Heller, Martin Fleisher, Howard I. Scher	2009	11
19	Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer Clinical Cancer Research ·David R. Shaffer, Margaret Leversha, Daniel C. Danila, Oscar Lin, Rita Gonzalez-Espinoza, Bin Gu, Aseem Anand, Katherine Smith, P. Maslak, Gerald V. Doyle, Leon W.M.M. Terstappen, Hans Lilja, Glenn Heller, Martin Fleisher, Howard I. Scher	2007	284
20	Truncated Activin Type I Receptor Alk4 Isoforms Are Dominant Negative Receptors Inhibiting Activin Signaling Molecular Endocrinology ·Yunli Zhou, Huiping Sun, Daniel C. Danila, Davood, Susan M. Covert, Xun Zhang, Anne Klibanski	2000	45

About Daniel C. Danila

Daniel C. Danila is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Radiology, Nuclear Medicine and Imaging and Endocrinology, Diabetes and Metabolism, having authored 130 papers that have together received 6.6k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (101 papers), Radiopharmaceutical Chemistry and Applications (45 papers), Cancer Genomics and Diagnostics (29 papers), Cancer Cells and Metastasis (15 papers), Cancer Immunotherapy and Biomarkers (11 papers), Cancer, Lipids, and Metabolism (10 papers), PARP inhibition in cancer therapy (9 papers) and Cancer Treatment and Pharmacology (9 papers). The work is most often cited by research in Cancer Research (2.8k citations), Pulmonary and Respiratory Medicine (4.0k citations), Oncology (2.5k citations), Endocrinology, Diabetes and Metabolism (1.1k citations) and Radiology, Nuclear Medicine and Imaging (948 citations). Daniel C. Danila has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Howard I. Scher, Martin Fleisher, Glenn Heller, Aseem Anand, Steven M. Larson, Michael J. Morris, Hans Lilja, Dana E. Rathkopf, Charles L. Sawyers and Rita Gonzalez-Espinoza. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, The Journal of Clinical Endocrinology & Metabolism, Clinical Cancer Research and European Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact